PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32537715-0	2020	Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach.	Fedratinib	48-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-91	
32537715-9	2020	These results serve as the basis for dose modifications of these CYP substrate drugs when co-administered with fedratinib.	Fedratinib	111-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68	
32537715-2	2020	In vitro studies indicated that fedratinib was an inhibitor of several cytochrome P450 (CYP) enzymes.	Fedratinib	32-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-86	
32537715-2	2020	In vitro studies indicated that fedratinib was an inhibitor of several cytochrome P450 (CYP) enzymes.	Fedratinib	32-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-91	
32537715-3	2020	The primary objective of this study was to evaluate the effects of repeated doses of fedratinib on the activity of CYP2D6, CYP2C19, and CYP3A4 in patients with solid tumors using a CYP probe cocktail.	Fedratinib	85-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-118